| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.13 | 5e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.19 | 0.0003 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0008 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.093 | 0.001 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.001 |